医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hutchison China MediTech Limited Announces Launch of Potential U.S. Public Offering of ADSs

2016年03月05日 AM03:13
このエントリーをはてなブックマークに追加


 

LONDON

Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the form of American depositary shares (“ADSs”) in the United States (the “Offering”).

The final price per ADS placed in the potential Offering will be determined following the book-building process. Chi-Med intends to grant the underwriters a 30-day option to purchase additional ADSs in connection with the potential Offering at the final offering price.

Chi-Med’s ordinary shares are currently admitted to trading on the AIM market of the London Stock Exchange under the symbol “HCM.” Chi-Med has applied to have its ADSs approved for listing on the Nasdaq Stock Market under the symbol “HCM.”

BofA Merrill Lynch and Deutsche Bank Securities (in alphabetical order) are acting as joint global coordinators and joint bookrunners for the potential Offering. Stifel, Canaccord Genuity, Panmure Gordon & Co. and CITIC CLSA are acting as co-managers for the potential Offering.

A registration statement on Form F-1 (the “Form F-1 Registration Statement”) relating to the ADSs has been filed with the United States Securities and Exchange Commission (the “SEC”) but has not yet become effective. The ADSs may not be sold nor may offers to buy be accepted prior to the time the Form F-1 Registration Statement becomes effective. The Form F-1 Registration Statement and all subsequent amendments may be accessed through the SEC’s website at www.sec.gov.

The Offering will be made only by means of a prospectus that will form part of the effective Form F-1 Registration Statement. Copies of the preliminary prospectus may be obtained from (in alphabetical order): (i) BofA Merrill Lynch, Attn: Prospectus Department, 222 Broadway, New York, NY 10038, or by email at dg.prospectus_requests@baml.com, or (ii) Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall Street, New York, NY 10005, or by email at prospectus.cpdg@db.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy ADSs or any other securities, nor shall there be any sale of ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Ends

Notes to Editors

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, including statements regarding the potential Offering. Actual results may differ materially from those projected or implied. More information about potential factors that could affect Chi-Med’s business and financial results is contained in the Form F-1 Registration Statement filed with the SEC. Any forward-looking statement made by Chi-Med herein, or elsewhere, speaks only as of the date on which such statement is made. Chi-Med does not intend, and undertakes no duty, to update any forward-looking statements after the date hereof to reflect future events or circumstances.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160304005671/en/

CONTACT

Chi-Med
Christian Hogg, CEO
Telephone: +852 2121 8200
or
Panmure
Gordon (UK) Limited

Richard Gray / Andrew Potts
Telephone:
+44 20 7886 2500
or
Citigate Dewe Rogerson,
Telephone:
+44 20 7638 9571
or
Anthony Carlisle
Mobile: +44 7973 611
888
or
David Dible
Mobile: +44 7967 566 919

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the United States
  • ニューランド・ラボラトリーズがプロセスエンジニアリング専用ラボを公開
  • 美泰上市全球最先进的人参补剂
  • SpinalCyteが新たな日本国特許を取得
  • Together for Safer Roads任命 David Braunstein担任总裁